Oncolytics Biotech Inc. Announces Commencement of Solicitation Process for Clinical Trials
CTEP is soliciting proposals for a Phase II study of REOLYSIN(R) administered systemically in patients with melanoma. The dosage and dosing regimen to be used in the study will be determined based on data derived from ongoing U.K. and U.S. Phase I systemic administration studies being conducted by Oncolytics.
CTEP is also soliciting proposals for a Phase I/II study of REOLYSIN(R) co-administered both systemically and intraperitoneally (IP) in patients with ovarian cancer. The purpose of the Phase I portion of the trial is to determine the Maximum Tolerated Dose (MTD) of REOLYSIN(R) given by IP administration in combination with a constant systemic dose and dosing regimen.
Oncolytics will provide REOLYSIN(R) for all clinical trials conducted and sponsored by the NCI under a Clinical Trials Agreement (CTA). The NCI initially approved REOLYSIN(R) for collaborative development after an analysis of preclinical, GLP toxicology and clinical data. Since the CTA was approved, Oncolytics and the NCI have worked together to select cancer indications and suitable development programs.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.